Mota, Ines https://orcid.org/0000-0003-1523-7134
Patrucco, Enrico
Mastini, Cristina https://orcid.org/0000-0001-5380-2611
Mahadevan, Navin R.
Thai, Tran C.
Bergaggio, Elisa https://orcid.org/0000-0002-9960-3674
Cheong, Taek-Chin https://orcid.org/0000-0002-0939-9412
Leonardi, Giulia
Karaca-Atabay, Elif
Campisi, Marco
Poggio, Teresa
Menotti, Matteo https://orcid.org/0000-0002-1260-2389
Ambrogio, Chiara https://orcid.org/0000-0003-4122-701X
Longo, Dario L. https://orcid.org/0000-0002-6906-9925
Klaeger, Susan https://orcid.org/0000-0002-0074-5163
Keshishian, Hasmik
Sztupinszki, Zsófia M. https://orcid.org/0000-0002-8691-4086
Szallasi, Zoltan https://orcid.org/0000-0001-5395-7509
Keskin, Derin B. https://orcid.org/0000-0002-8496-6181
Duke-Cohan, Jonathan S. https://orcid.org/0000-0002-9478-9609
Reinhold, Bruce
Carr, Steven A. https://orcid.org/0000-0002-7203-4299
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Moynihan, Kelly D.
Irvine, Darrell J. https://orcid.org/0000-0002-8637-1405
Barbie, David A.
Reinherz, Ellis L. https://orcid.org/0000-0003-1048-5526
Voena, Claudia https://orcid.org/0000-0002-1324-1431
Awad, Mark M.
Blasco, Rafael B. https://orcid.org/0000-0001-8025-0306
Chiarle, Roberto https://orcid.org/0000-0003-1564-8531
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA265826-01A1, U24CA224331, 1R01HL157174-01A1, U24CA224331, P50 CA265826-01A1, P50 CA265826-01A1)
American-Italian Cancer Foundation
U.S. Department of Defense (W81XWH-18-1-0751, W81XWH-18-1-0751)
Breast Cancer Research Foundation (BCRF-21-159, BCRF-21-159)
U.S. Department of Health & Human Services | National Institutes of Health (EB022433)
Article History
Received: 23 February 2022
Accepted: 7 June 2023
First Online: 10 July 2023
Competing interests
: R.C. and R.B.B. have filed IP related to human ALK vaccine sequences. R.C. and D.J.I. hold stock options in Elicio Therapeutics. D.J.I. is a consultant to Elicio Therapeutics. R.B.B. is a current employee of Moderna Therapeutics. C.J.W. receives research funding from Pharmacyclics and holds equity in BioNTech, Inc. D.B.K. is a scientific advisor for Immunitrack and Breakbio. D.B.K. owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Celldex Therapeutics, Editas Medicine, Gilead Sciences, Immunitybio, ImmunoGen, IMV, Lexicon Pharmaceuticals and Neoleukin Therapeutics. BeiGene, a Chinese biotech company, supported unrelated severe acute respiratory syndrome coronavirus 2 research at Translational Immunogenomics Lab (TIGL) at DFCI.